The combined PD-L1 immune checkpoint inhibitor (ICI) treatment significantly potentiated the anti-tumor effect of this BNT162b2-based cancer therapeutic strategy, and in some cases, tumor nodules were eliminated by the combined therapy. This evidence concerns the gene CD274 and neoplasm.